

Datasheet: HCA360

BATCH NUMBER 163200

Description:	HUMAN ANTI DURVALUMAB
Specificity:	DURVALUMAB
Format:	Purified
Product Type:	Monoclonal Antibody
Clone:	AbD41313ia
Isotype:	IgG1
Quantity:	0.1 mg

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
ELISA	▪			

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

Target Species	Drug
Product Form	Human IgG1 antibody (lambda light chain) selected from the HuCAL phage display library and expressed in a human cell line. This antibody is supplied as a liquid.
Preparation	Purified IgG prepared by affinity chromatography on Protein A
Buffer Solution	Phosphate buffered saline
Preservative Stabilisers	0.01% Thiomersal
Approx. Protein Concentrations	Antibody concentration 0.5 mg/ml
Immunogen	Durvalumab
Specificity	Human Anti-Durvalumab Antibody, clone AbD41313ia is a paratope specific, inhibitory

anti-idiotypic antibody (Type 1) that specifically recognizes the free human monoclonal antibody drug durvalumab. The antibody does not recognize free PD-L1 nor durvalumab in complex with PD-L1.

Clone AbD41313ia is a fully human recombinant monoclonal antibody with IgG1 isotype and can be used as a surrogate positive control or reference standard in an anti-drug antibody (ADA) assay. This antibody has a monovalent intrinsic affinity of 14 nM, and is one of two antibodies with different affinities offered for ADA assays.

[ADA bridging ELISA](#)

HCA360 may also be used as the detection antibody together with the Anti-Durvalumab monovalent Fab antibody [TZA004](#), as capture antibody in a pharmacokinetic (PK) assay to measure free durvalumab captured via immobilized PD-L1.

[PK bridging ELISA](#)

Durvalumab (Imfinzi) is a human IgG1/kappa antibody with allotype G1m3. The CH2 domain was engineered with three amino acid substitutions (L238F, L239E, P335S) to reduce the Fc-mediated effector functions to prevent depletion of PD-L1+ T-cells. It was first approved for previously treated patients with advanced bladder cancer. It was later approved for the treatment of unresectable stage 3 NSCLC (Non-Small Cell Lung Cancer) and ES-SCLC. Durvalumab binds to PD-L1 to block the interaction with the inhibitory T cell receptor PD-1. This blockade removes the suppression of T-cells that are specific for MHC-1-presented neoepitopes on tumor cells. Removal of this inhibitory signal leads to the release of granzymes and perforins by the activated T-cells, and finally to the destruction of the tumor cells.

[View a summary of all anti-durvalumab antibodies](#)

Affinity

The intrinsic affinity of the monovalent form of Human anti Durvalumab antibody, clone AbD41313ia is $K_D = 14$ nM as measured by real time, label free molecular interaction analysis on immobilized Durvalumab.

ELISA

This product may be used in a direct or indirect ELISA or as a detection reagent for durvalumab in a PK bridging ELISA together with [TZA004](#) (AbD41327) as the capture reagent. It can also be used to develop and calibrate anti drug antibody (ADA) assays to measure the ADA response in patient sera together with [HCA359](#) and [HCA361](#)

Protocol: [ADA bridging ELISA](#).

Storage

This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.

Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended.

Guarantee	12 months from date of despatch
Acknowledgements	This product and/or its use is covered by claims of U.S. patents, and/or pending U.S. and non-U.S. patent applications owned by or under license to Bio-Rad Laboratories, Inc. See bio-rad.com/en-us/trademarks for details. Imfinzi is a trademark of Medimmune/AstraZeneca using Abgenix's XenoMouse technology.
Health And Safety Information	Material Safety Datasheet documentation #10094 available at: 10094: https://www.bio-rad-antibodies.com/uploads/MSDS/10094.pdf
Licensed Use	For <i>in vitro</i> research purposes and for commercial applications for the provision of <i>in vitro</i> testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.
Regulatory	For research purposes only
Technical Advice	Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual .

Related Products

Recommended Useful Reagents

[LYNX RAPID HRP ANTIBODY CONJUGATION KIT \(LNK002P\)](#)

[HISPEC ASSAY DILUENT \(BUF049A\)](#)

[HUMAN ANTI DURVALUMAB \(HCA359\)](#)

ELISA Matched Pair - Capture Antibody

[HUMAN ANTI DURVALUMAB \(TZA004\)](#)

North & South America	Tel: +1 800 265 7376 Fax: +1 919 878 3751 Email: antibody_sales_us@bio-rad.com	Worldwide	Tel: +44 (0)1865 852 700 Fax: +44 (0)1865 852 739 Email: antibody_sales_uk@bio-rad.com	Europe	Tel: +49 (0) 89 8090 95 21 Fax: +49 (0) 89 8090 95 50 Email: antibody_sales_de@bio-rad.com
----------------------------------	---	------------------	---	---------------	---

To find a batch/lot specific datasheet for this product, please use our online search tool at: bio-rad-antibodies.com/datasheets
'M412559:221114'

Printed on 02 Mar 2023